首页> 美国卫生研究院文献>Immunology >Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice
【2h】

Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice

机译:B7.1在表达MUC1的小鼠乳腺上皮肿瘤细胞系中的表达抑制致瘤性,但不诱导MUC1转基因小鼠的自身免疫

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The MUC1 epithelial mucin, which is overexpressed and aberrantly glycosylated in breast and other carcinomas, is also expressed on the apical surface of most normal glandular epithelial cells. Since clinical trials evaluating the efficacy of MUC1- based vaccines have been initiated in breast cancer patients, it is important to address the question of whether an effective immune response to the cancer associated mucin can be generated without inducing autoimmunity. Since non-classic cytotoxic T lymphocyte (CTL) responses to MUC1 have been reported, it is also relevant to examine the role of costimulatory molecules in the effective presentation of MUC1 based antigens. We have therefore looked at the effect of expressing B7.1 on the tumorigenicity of a MUC1 expressing mammary epithelial cell line (410.4) in a transgenic mouse expressing MUC1 on its normal glandular epithelial tissues. Coexpression of B7.1 with MUC1 in 410.4 cells resulted in a dramatic inhibition of tumour growth which depended on the activity of CD4+and CD8+ T cells. The epithelial tissues in the transgenic mice able to reject the B7.1, MUC1-expressing tumours showed no evidence of degeneration and the mice survived their normal life span. The results demonstrate that an immune response to the MUC1 antigen can be induced in MUC1 transgenic mice and that presentation of the antigen, whether directly or by cross-priming, is markedly enhanced by coexpression of B7.1.
机译:MUC1上皮粘蛋白在乳腺癌和其他癌中过表达且糖基化,在大多数正常腺上皮细胞的顶表面也表达。由于已经开始在乳腺癌患者中评估基于MUC1的疫苗的疗效的临床试验,因此重要的是要解决以下问题:是否可以在不诱导自身免疫的情况下产生针对癌症相关粘蛋白的有效免疫应答。由于已经报道了对MUC1的非经典细胞毒性T淋巴细胞(CTL)反应,因此检查共刺激分子在基于MUC1的抗原的有效呈递中的作用也很重要。因此,我们已经研究了在正常腺体上皮组织中表达MUC1的转基因小鼠中,表达B7.1对表达MUC1的乳腺上皮细胞系(410.4)致瘤性的影响。 B7.1与MUC1在410.4细胞中的共表达导致对肿瘤生长的显着抑制,这取决于CD4 + 和CD8 + T细胞的活性。能够排斥表达B7.1,MUC1的肿瘤的转基因小鼠的上皮组织没有变性的证据,并且小鼠可以正常生存。结果表明,可以在MUC1转基因小鼠中诱导对MUC1抗原的免疫应答,并且通过直接表达B7.1可以显着增强抗原的呈递,无论是直接还是通过交叉引物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号